-
公开(公告)号：US11059794B2
公开(公告)日：2021-07-13
申请号：US16569475
申请日：2019-09-12
发明人： Patrizio Mattei , Jérôme Hert , Daniel Hunziker , Markus Rudolph , Petra Schmitz , Patrick Di Giorgio , Justin Gomme
IPC分类号： C07D257/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D405/12 , C07D405/14 , C07D409/14 , C07D417/14
摘要： The invention provides novel compounds having the general formula (I) wherein R1, R2, Y, X, W, m and n are as defined herein, compositions including the compounds and methods of using the compounds.
-
112.发明申请公开(公告)号：US20210188992A1
公开(公告)日：2021-06-24
申请号：US17179223
申请日：2021-02-18
发明人： Peter BRUENKER , Alexander BUJOTZEK , Harald DUERR , Guy GEORGES , Christian KLEIN , Stephane LECLAIR , Moritz RAPP , Eva Carina SUM , Christine TRUMPFHELLER , Pablo UMAÑA
摘要： The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and (b) at least one antigen binding domain capable of specific binding to a target cell antigen, in particular Fibroblast Activation Protein (FAP), and to methods of producing these molecules and to methods of using the same.
-
公开(公告)号：US11034699B2
公开(公告)日：2021-06-15
申请号：US16220512
申请日：2018-12-14
发明人： Barbara Biemans , Wolfgang Guba , Georg Jaeschke , Lothar Lindemann , Fionn O'Hara , Antonio Ricci , Daniel Rueher , Eric Vieira
IPC分类号： C07D401/10 , C07D471/10 , C07D487/10 , C07D491/107 , C07D491/20 , A61K31/527 , A61P35/00 , A61P25/22 , A61P3/10 , A61P25/24 , A61P25/00 , A61P25/16 , A61P1/08
摘要： The present invention relates to positive allosteric modulators (PAMs) of metabotropic glutamate receptor 4 (mGluR4) that may be used for the treatment of conditions such as Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression and diabetes type 2.
-
公开(公告)号：US20210171619A1
公开(公告)日：2021-06-10
申请号：US17177543
申请日：2021-02-17
摘要： Herein is reported a recombinant fusion polypeptide comprising an antibody heavy chain variable domain, a multimerization domain and an antibody light chain variable domain, wherein the antibody heavy chain variable domain is fused (either directly or via a first (peptidic) linker) to one terminus of the multimerization domain, the antibody light chain variable domain is fused (either directly or via a second (peptidic) linker) to the respective other terminus of the multimerization domain, and the antibody heavy chain variable domain or the antibody light chain variable domain has a (intra-peptidic) disulphide bond to the multimerization domain.
-
公开(公告)号：US20210171441A1
公开(公告)日：2021-06-10
申请号：US16930013
申请日：2020-07-15
发明人： Olivier Gavelle , Uwe Grether , Matthias Nettekoven , Stephan Roever , Mark Rogers-Evans , Didier Rombach
IPC分类号： C07C235/52 , C07D209/54 , C07D231/12 , C07D205/04 , C07D401/10 , C07D277/28 , C07D413/12 , C07C231/02 , C07D213/61 , C07D207/14 , C07D207/16 , C07D207/10 , C07C235/48 , C07D305/06 , C07D331/04 , C07D403/10 , C07D413/06 , C07D413/10 , C07D305/08 , C07C237/22 , C07D271/06 , C07D277/30
摘要： The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
-
公开(公告)号：US11021448B2
公开(公告)日：2021-06-01
申请号：US16399134
申请日：2019-04-30
发明人： Alexander Flohr
IPC分类号： C07D243/24 , C07D243/22 , C07D401/04 , A61P25/28 , A61P25/18
摘要： The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.
-
公开(公告)号：US11014963B2
公开(公告)日：2021-05-25
申请号：US16121300
申请日：2018-09-04
IPC分类号： C07K5/083 , C07K5/08 , C07K5/087 , C07K5/097 , C07K5/093 , A61P43/00 , A61P27/02 , A61P27/00 , A61P9/00 , A61P9/10 , C07K5/062 , C07K5/09 , C07K5/072 , C07K5/068 , C07K5/078 , C07K5/065 , C07K5/06
摘要： The invention provides novel compounds having the general formula (I) wherein R2, R3, R4, R5, R6, R7, R3, R8, R10, R11 and R23 are as described herein, compositions including the compounds and methods of using the compounds.
-
公开(公告)号：US20210123054A1
公开(公告)日：2021-04-29
申请号：US17139161
申请日：2020-12-31
IPC分类号： C12N15/113
摘要： The present invention relates to antisense oligonucleotides that are capable of modulating expression of Tau in a target cell. The oligonucleotides hybridize to MAPT mRNA. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of Tauopathies, Alzheimzer's disease, fronto-temporal dementia (FTD), FTDP-17, progressive supranuclear palsy (PSP), chronic traumatic encephalopathy (CTE), corticobasal ganglionic degeneration (CBD), epilepsy, Dravet syndrome, depression, seizure disorders and movement disorders.
-
公开(公告)号：US20210115141A1
公开(公告)日：2021-04-22
申请号：US17074471
申请日：2020-10-19
IPC分类号： C07K16/28 , A61P35/00 , A61K31/7068 , A61K31/555 , A61K47/68 , A61K9/00
摘要： Provided herein are methods of treating B-cell proliferative disorders (such as diffuse large B-cell lymphoma (DLBCL)) using immunoconjugates comprising anti-CD79b antibodies in combination with an anti-CD20 antibody (such as rituximab) and one or more chemotherapeutic agents (such as gemcitabine and oxaliplatin).
-
公开(公告)号：US20210115027A1
公开(公告)日：2021-04-22
申请号：US17125647
申请日：2020-12-17
发明人： Simon M. Ametamey , Kenneth Atz , Luca Gobbi , Uwe Grether , Wolfgang Guba , Julian Kretz
IPC分类号： C07D405/14 , C07D401/04 , A61K9/20 , A61K9/28 , A61K9/48 , A61K9/08 , A61K47/34 , A61K47/12
摘要： The invention relates to a compound of formula (I) wherein A1, A2 and R1-R5 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
-
-
-
-
-
-
-
-
-
搜索结果
5476 条记录 (耗时 0.052 秒)
